Table 4 Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with levcromakalim
From: The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine
Paper | Study design | Dose (daily) | Indication | No. of patients | Headache No. |
|---|---|---|---|---|---|
Singer et al. 1989, J. Hypertens [98]. | RCT | 1.5Â mg | Essential hypertension | 8 | 4 (50%) |
Williams et al. 1990, Lancet [60]. | RCT | 1.5Â mg | Asthma | 16 | 10 (62%) |
Kidney et al. 1993, Thorax [62]. | RCT | 0.125–0.5 mg | Asthma | 25 | 19 (76%) |
Suzuki et al. 1995, Arzneim.-Forsch./Drug Res [99]. | Open label | 0.5–1.0 mg | Essential hypertension | 14 | 4 (29%) |